1032754-93-0 | Apitolisib

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$59.00	$41.00
5mg	95%	in stock	$86.00	$60.00
10mg	95%	in stock	$121.00	$85.00
25mg	95%	in stock	$268.00	$188.00
50mg	95%	in stock	$345.00	$242.00
100mg	95%	in stock	$582.00	$408.00

Description

• Catalog Number: AB47525
• Chemical Name: Apitolisib
• CAS Number: 1032754-93-0
• Molecular Formula: C23H30N8O3S
• Molecular Weight: 498.6011
• MDL Number: MFCD20274520
• SMILES: O=C(N1CCN(CC1)Cc1sc2c(c1C)nc(nc2N1CCOCC1)c1cnc(nc1)N)[C@@H](O)C

Upstream Synthesis Route

Apitolisib, also known as GDC-0980, is a potent and selective inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). In chemical synthesis, Apitolisib plays a crucial role as a tool compound for studying the PI3K/mTOR pathway and its implications in various biological processes. Its high specificity and efficacy make it a valuable asset in the development of pharmaceuticals targeting cancer and other diseases where dysregulation of the PI3K/mTOR pathway is implicated.Apitolisib is utilized in chemical synthesis to investigate the molecular mechanisms underlying cell growth, proliferation, and survival. By inhibiting PI3K and mTOR, Apitolisib can modulate key signaling pathways involved in these cellular processes, offering valuable insights into the development and progression of diseases such as cancer. Its ability to selectively target specific components of the PI3K/mTOR pathway makes Apitolisib a powerful tool for dissecting complex cellular signaling networks.Additionally, Apitolisib's role in chemical synthesis extends to the identification and validation of potential drug targets and compounds for therapeutic interventions. Its pharmacological properties and unique mode of action make it a promising candidate for the development of novel anticancer agents and precision medicine approaches. Through its application in chemical synthesis, Apitolisib contributes to advancing our understanding of disease pathways and facilitates the discovery of innovative treatments with improved efficacy and safety profiles.